AN ARTHRITIS drug slashes the risk of Covid death by a fifth in the sickest patients, real-world trials reveal.
Anti-inflammatory pill baricitinib is now the fourth therapy shown to cut mortality in seriously ill coronavirus victims.
Experts said its life-saving effects are in addition to the benefits of other proven pandemic treatments, such as dexamethasone.
More than 8,000 Brits in hospital with Covid were either given the arthritis drug or a dummy pill.
Oxford University researchers found patients treated with baricitinib for ten days were 20 per cent less likely to die.
Joint chief investigator of the RECOVERY trial Sir Martin Landray praised the findings of the study.
He said: “Today’s results not only show that treatment with baricitinib improves the chances of survival for patients with severe Covid-19, but that this benefit is additional to that from other treatments that dampen down the over-active immune response, such as dexamethasone and tocilizumab.
“This opens up the possibility of using combinations of anti-inflammatory drugs to further drive down the risk of death for some of the sickest patients.”
The Oxford team have previously discovered three other life-saving Covid treatments – the steroid dexamethasone, the arthritis treatment tocilizumab, and a monoclonal antibody therapy called Ronapreve.
Dexamethasone is a corticosteriod drug, typically used to treat rheumatic problems, several skin diseases and some respiratory infections like asthma and chronic obstructive lung disease.
Tocilizumab – which is marketed as Actemra – is normally taken by those crippled with the painful condition to help reduce chronic inflammation.
Ronapreve works by injecting virus-fighting antibodies into the blood, where they latch on to the coronavirus and stop it getting into cells.
